TY - JOUR
T1 - Relapse factors for ileal neuroendocrine tumours after curative surgery
T2 - A retrospective French multicentre study
AU - Le Roux, Catherine
AU - Lombard-Bohas, Catherine
AU - Delmas, Christelle
AU - Dominguez-Tinajero, Sophie
AU - Ruszniewski, Philippe
AU - Samalin, Emmanuelle
AU - Raoul, Jean Luc
AU - Renard, Pascal
AU - Baudin, Eric
AU - Robaskiewicz, Michel
AU - Mitry, Emmanuel
AU - Cadiot, Guillaume
PY - 2011/10/1
Y1 - 2011/10/1
N2 - Aim: To evaluate the characteristics of postoperative relapse, predictive factors and time to relapse after curative surgery for well-differentiated neuroendocrine tumours of the ileum, without hepatic or other distant metastases. Methods: Clinical data of patients entered into the Groupe d'étude des Tumeurs Endocrines database were collected and analysed retrospectively to identify factors predictive of relapse. Results: Among 100 patients followed for a median of 56.5 (range 1-290) months, 42 relapsed after a median follow-up of 57.5 (range 6-176) months, with liver lesions in 27 (64.3%). Median disease-free survival (Kaplan-Meier) was 88 months (95% confidence interval 72-115). Disease-free survival was shorter for emergency surgery patients (p<. 0.01), patients with distant mesenteric lymph-node metastases (p<. 0.01), with fortuitous diagnosis (p= 0.02), with tumour diameter >20. mm (p= 0.02), and those with multiple tumours (p= 0.07). Multivariate analysis retained emergency surgery (odds-ratio 4.04 [95% confidence interval 2.01-8.11]), distant mesenteric lymph-node metastases (odds-ratio 2.53 [95% confidence interval 1.22-5.25]), and multiple tumours (odds-ratio 2.14 [95% confidence interval 1.01-4.50]), as being significantly associated with relapse. Conclusion: Patients who underwent emergency surgery, with distant mesenteric lymph-node metastases or with multiple ileal tumours relapsed earlier. Closer monitoring for the patients with these risk factors may be required.
AB - Aim: To evaluate the characteristics of postoperative relapse, predictive factors and time to relapse after curative surgery for well-differentiated neuroendocrine tumours of the ileum, without hepatic or other distant metastases. Methods: Clinical data of patients entered into the Groupe d'étude des Tumeurs Endocrines database were collected and analysed retrospectively to identify factors predictive of relapse. Results: Among 100 patients followed for a median of 56.5 (range 1-290) months, 42 relapsed after a median follow-up of 57.5 (range 6-176) months, with liver lesions in 27 (64.3%). Median disease-free survival (Kaplan-Meier) was 88 months (95% confidence interval 72-115). Disease-free survival was shorter for emergency surgery patients (p<. 0.01), patients with distant mesenteric lymph-node metastases (p<. 0.01), with fortuitous diagnosis (p= 0.02), with tumour diameter >20. mm (p= 0.02), and those with multiple tumours (p= 0.07). Multivariate analysis retained emergency surgery (odds-ratio 4.04 [95% confidence interval 2.01-8.11]), distant mesenteric lymph-node metastases (odds-ratio 2.53 [95% confidence interval 1.22-5.25]), and multiple tumours (odds-ratio 2.14 [95% confidence interval 1.01-4.50]), as being significantly associated with relapse. Conclusion: Patients who underwent emergency surgery, with distant mesenteric lymph-node metastases or with multiple ileal tumours relapsed earlier. Closer monitoring for the patients with these risk factors may be required.
KW - Emergency surgery
KW - Ileum
KW - Liver metastases
KW - Multiple tumours
KW - Neuroendocrine tumours
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=80052487981&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2011.04.021
DO - 10.1016/j.dld.2011.04.021
M3 - Article
C2 - 21641888
AN - SCOPUS:80052487981
SN - 1590-8658
VL - 43
SP - 828
EP - 833
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 10
ER -